Page last updated: 2024-12-06
metflurazon
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
metflurazon: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 32011 |
SCHEMBL ID | 135108 |
MeSH ID | M0041853 |
Synonyms (31)
Synonym |
---|
metflurazon |
4-chloro-5-(dimethylamino)-2-[3-(trifluoromethyl)phenyl]pyridazin-3-one |
4-chloro-5-(dimethylamino)-2-alpha,alpha,alpha-(trifluoro-m-tolyl)-3-(2h)-pyridazinone |
4-chloro-5-dimethylamino-2-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridazin-3(2h)-one |
san-6706 |
sandoz 6706 |
nt6hy78wbn , |
23576-23-0 |
unii-nt6hy78wbn |
metflurazon [iso] |
3(2h)-pyridazinone, 4-chloro-5-(dimethylamino)-2-(3-(trifluoromethyl)phenyl)- |
san 6706-3197 |
S-6706 , |
1-m-trifluoromethylphenyl-4-dimethylamino-5-chloropyridaz-6-one |
4-chloro-5-dimethylamino-2-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)pyridazin-3(2h)-one |
methylnorflurazon |
3(2h)-pyridazinone, 4-chloro-5-(dimethylamino)-2-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)- |
sandoz-6706 |
4-chloro-5-(dimethylamino)-2,3-dihydro-2-(3-(trifluoromethyl)phenyl)-3-pyridazinone |
metflukazone |
4-chloro-5-(dimethylamino)-2-((3-trifluoromethyl)phenyl)-3(2h)-pyridazinone |
4-chloro-5-(dimethylamino)-2-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-3(2h)-pyridazinone |
metflurazone |
san-h-6706 |
SCHEMBL135108 |
DTXSID8042133 |
4-chloro-5-dimethylamino-2-[3-(trifluoromethyl)phenyl]pyridazin-3-one |
4-chloro-5-(dimethylamino)-2-(3-(trifluoromethyl)phenyl)pyridazin-3(2h)-one , |
Q27285043 |
cyqmvkqkbffdoo-uhfffaoysa-n |
AKOS040753011 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |